Galmed Pharmaceuticals (NASDAQ:GLMD) was downgraded by stock analysts at ValuEngine from a “hold” rating to a “sell” rating in a report issued on Friday.

GLMD has been the subject of a number of other research reports. HC Wainwright reissued a “buy” rating and set a $18.00 target price on shares of Galmed Pharmaceuticals in a research note on Friday, October 27th. Seaport Global Securities reissued a “buy” rating and set a $19.00 target price on shares of Galmed Pharmaceuticals in a research note on Friday, October 6th. Zacks Investment Research upgraded shares of Galmed Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.50 price target on the stock in a report on Tuesday, November 14th. Roth Capital began coverage on shares of Galmed Pharmaceuticals in a report on Wednesday, November 15th. They set a “buy” rating and a $32.00 price target on the stock. Finally, Maxim Group set a $14.00 price target on shares of Galmed Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, October 5th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. Galmed Pharmaceuticals has an average rating of “Buy” and a consensus price target of $18.30.

Shares of Galmed Pharmaceuticals (NASDAQ GLMD) traded down $0.07 during trading hours on Friday, hitting $7.97. 41,862 shares of the company’s stock were exchanged, compared to its average volume of 33,672. Galmed Pharmaceuticals has a 52 week low of $3.04 and a 52 week high of $9.59.

An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. GRT Capital Partners L.L.C. purchased a new stake in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 18,314 shares of the biopharmaceutical company’s stock, valued at approximately $114,000. GRT Capital Partners L.L.C. owned approximately 0.15% of Galmed Pharmaceuticals at the end of the most recent quarter. Hedge funds and other institutional investors own 9.85% of the company’s stock.

WARNING: This piece was originally reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/03/galmed-pharmaceuticals-glmd-downgraded-by-valuengine-to-sell.html.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Galmed Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.